Sanjeev Forsyth

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang et al. · The Lancet Haematology · 2022 · 111 citations · Full text

Phase 1/2, Hematological Malignancy, Myelodysplastic Syndrome +9

Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial

Macarena I. de la Fuente, Howard Colman, Mark Rosenthal et al. · Neuro-Oncology · 2022 · 65 citations · Full text

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

Patricia Schroeder, Keertik Fulzele, Sanjeev Forsyth et al. · Journal of Pharmacology and Experimental Therapeutics · 2022 · 37 citations · Full text

Sickle Cell Disease, Healthy Subjects, Health Sciences +12

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial

Sanjeev Forsyth, Patricia Schroeder, James Geib et al. · Clinical Pharmacology in Drug Development · 2022 · 27 citations · Full text

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts, Maria R. Baer, Jay Yang et al. · Blood · 2019 · 26 citations